TC-6987 / Gyre Therapeutics - LARVOL DELTA

Glycemic control, safety and tolerability of TC-6987 monotherapy in type 2 diabetes mellitus (clinicaltrials.gov) - P2, N=120; Recruiting -> Active, not recruiting

Enrollment open • Diabetes

Targacept: Annual Report 2012 (Targacept) - Anticipated patent expiry of composition of matter for a family of racemic compounds that includes a racemic mixture that includes TC-6987 in Aug 2019; Anticipated patent expiry of composition of matter for a sub-family of racemic compounds that includes a racemic mixture that includes TC-6987 in Dec 2018

Anticipated patent expiry • Pain